6
NMR (100 MHz, CDCl3, δ): 87.4, 81.7, 61.3(2C), 48.2, 48.1,
40.2, 34.1, 31.3, 25.9, 22.7, 22.4, 22.1, 21.1(2C), 15.8; IR
(/cm-1): 2995, 2920, 1200, 1050.
5.8 Hz, 4H), 1.50-1.47 (m, 2H), 1.20-1.18 (m, 2H), 2.05–
0.90 (m, 9H), 0.91 (t, J = 7.2 Hz, 3H), 0.88 (d, J = 7.0 Hz,
3H), 0.76 (d, J = 6.7 Hz, 3H), 0.68 (d, J = 6.5 Hz, 3H); 13C
NMR (100 MHz, CDCl3, δ): 164.5, 77.4, 71.0, 64.3, 64.2,
60.9, 46.5, 40.4, 33.7, 31.3, 26.2, 25.6, 22.9, 21.8, 21.6, 21.0,
20.6, 19.6, 16.1, 13.6; IR (/cm-1): 2983, 1742, 1188, 1091.
Table
1,
1g:
Methyl
[(1R,2S,5R)-(-)-
menthoxymethyl]pyrrolidinium
bis(trifluoromethane)sulfonamide (semisolid; yield = 84.4%),
[]20 -36.3; 1H NMR (400 MHz, CDCl3, ): 4.55, 4.50 (d, J
Table
2,
2a:
Butyl
[(1R,2S,5R)-(-)-
D
menthoxyacetyl]pyrrolidinium tetrafluoroborate (solid; m.p. =
= 8.0 Hz, 2H), 3.56 (t, J = 5.9 Hz, 2H), 3.42 (dt, J = 4.4, 8.0
Hz, 1H), 3.38 (t, J = 5.9 Hz, 2H), 3.03 (s, 3H), 2.20 (t, J = 5.8
Hz, 4H), 2.02-0.90 (m, 9H), 0.87 (d, J = 7.8 Hz, 6H), 0.75 (d,
J = 7.9 Hz, 3H); 13C NMR (100 MHz, CDCl3, δ): 121.8,
118.9, 87.7, 81.7, 61.4(2C), 48.1, 48.0, 40.2, 34.0, 31.2, 25.9,
22.8, 22.2, 22.1, 21.9(2C), 15.7; IR (/cm-1): 2996, 2912,
1290, 1030.
52-54 oC; yield = 81.7%), []20 - 42.1; 1H NMR (400 MHz,
D
CDCl3, ): 4.77 (dt, J = 4.0, 10.7 Hz, 1H), 4.13, 4.11 (d, J =
7.6 Hz, 2H), 3.79 (t, J = 5.8 Hz, 4H), 3.37 (t, J = 5.9 Hz, 2H),
2.23 (t, J = 5.7 Hz, 4H), 1.67-1.65 (m, 2H), 1.36-1.34 (m,
2H), 2.12–0.98 (m, 9H), 0.92 (t, J = 7.1 Hz, 3H), 0.87 (d, J =
7.0 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H), 0.69 (d, J = 6.6 Hz,
3H); 13C NMR (100 MHz, CDCl3, δ): 164.4, 77.6, 71.5, 64.7,
64.5, 61.1, 46.7, 40.4, 34.6, 31.5, 25.9, 25.7, 23.2, 22.2, 21.9,
21.0, 20.7, 19.6, 16.0, 13.5; IR (/cm-1): 2973, 1748, 1211,
1033.
Table
1,
1h:
Methyl
[(1R,2S,5R)-(-)-
menthoxymethyl]pyrrolidinium L-lactate (semisolid; yield =
1
86.4%), []20 -67.8; H NMR (400 MHz, CDCl3, ): 4.89,
D
4.73 (d, J = 7.0 Hz, 2H), 3.94 (q, J = 5.4 Hz, 1H), 3.80 (t, J =
5.8 Hz, 2H), 3.64 (t, J = 5.8 Hz, 2H), 3.48 (dt, J = 4.4, 8.0 Hz,
1H), 3.28 (s, 3H), 2.76 (bs, 1H, OH), 2.25 (t, J = 5.9 Hz, 4H),
1.55 (d, J = 5.9 Hz, 3H), 2.14-0.92 (m, 9H), 0.87 (d, J = 7.8
Hz, 6H), 0.82 (d, J = 7.9 Hz, 3H); 13C NMR (100 MHz,
CDCl3, δ): 180.1, 87.3, 81.5, 71.4, 61.0(2C), 48.6, 48.2, 40.2,
34.0, 31.6, 25.9, 22.3, 22.2, 22.1, 21.1(2C), 21.0, 16.1; IR
(/cm-1): 3580-2525 (br), 2970, 1730, 1200, 1025.
Table
2,
2b:
Butyl
[(1R,2S,5R)-(-)-
menthoxyacetyl]pyrrolidinium hexafluorophosphate (solid;
m.p. = 38-39 oC; yield = 87.7%), []20 -40.2; 1H NMR (400
D
MHz, CDCl3, ): 4.76 (dt, J = 4.2, 11.0 Hz, 1H), 4.07, 4.02
(d, J = 7.6 Hz, 2H), 3.67 (t, J = 5.9 Hz, 4H), 3.37 (t, J = 5.4
Hz, 2H), 2.21 (t, J = 5.7 Hz, 4H), 1.60-1.58 (m, 2H), 1.39-
1.36 (m, 2H), 2.09–0.92 (m, 9H), 0.93 (t, J = 7.0 Hz, 3H),
0.88 (d, J = 7.0 Hz, 3H), 0.76 (d, J = 6.7 Hz, 3H), 0.71 (d, J =
6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3, δ): 164.1, 77.4,
71.6, 64.8, 64.6, 61.4, 46.7, 40.3, 33.9, 31.7, 25.3, 25.0, 23.4,
21.9, 21.8, 21.6, 20.7, 19.5, 16.0, 13.4; IR (/cm-1): 2979,
1750, 1207, 1056.
16. Procedure for the synthesis of (1R,2S,5R)-(-)-menthyl
chloroacetate: (1R,2S,5R)-(-)-menthol (0.10 mol) was reacted
with chloroacetyl chloride (0.11 mol) and trimethylamine
(0.11 mol) in THF, stirring overnight at room temperature.
After the reaction time, the solvent was evaporated and the
product was purified by silica gel flash column
chromatography using a gradient mixture of hexanes/ethyl
Table
2,
2c:
Butyl
[(1R,2S,5R)-(-)-
menthoxyacetyl]pyrrolidinium
bis(trifluoromethane)sulfonimide (liquid; yield = 92.8%)
1
[]20 -32.1; H NMR (400 MHz, CDCl3, ): 4.80 (dt, J =
1
acetate as the mobile phase. (85.6%); H NMR (400 MHz,
D
CDCl3, ): 4.70 (dt, J = 6.0, 11.0 Hz, 1H), 3.97 (s, 2H), 2.14-
0.91 (m, 9H), 0.86 (d, J = 7.9 Hz, 6H), 0.73 (d, J = 7.8 Hz,
3H); 13C NMR (100 MHz, CDCl3, δ): 166.9, 87.4, 81.7,
61.3(2C), 48.2, 48.1, 40.2, 34.1, 31.3, 25.9, 22.7, 22.4, 22.1,
21.1(2C), 15.8; IR (/cm-1): 2995, 2920, 1200, 1050.
4.0, 10.6 Hz, 1H), 4.10, 4.09 (d, J = 7.5 Hz, 2H), 3.70 (t, J =
5.8 Hz, 4H), 3.38 (t, J = 5.4 Hz, 2H), 2.24 (t, J = 5.7 Hz, 4H),
1.67-1.66 (m, 2H), 1.41-1.37 (m, 2H), 2.13–0.98 (m, 9H),
0.95 (t, J = 6.8 Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H), 0.77 (d, J =
6.7 Hz, 3H), 0.72 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz,
CDCl3, δ): 164.1, 120.9, 118.0, 77.2, 71.5, 64.7, 64.6, 61.4,
46.7, 40.3, 33.9, 31.7, 25.6, 25.2, 23.6, 21.8, 21.7, 21.0, 20.6,
19.5, 16.0, 13.3; IR (/cm-1): 2991, 1744, 1284, 1006.
17. Representative Procedure for the Synthesis of alkyl
[(1R,2S,5R)-(-)-menthoxyacetyl]pyrrolidinium ionic liquids
(2a – 2h): In a round-bottomed flask, 1-alkylpyrrolidine (0.01
mol) was mixed with (1R,2S,5R)-(-)-menthyl chloroacetate
(0.01 mol) in acetonitrile under nitrogen atmosphere. The
reaction mixture was heated to reflux for 48 h. After the
reaction time, the solvent was evaporated using a rotary
evaporator and the resultant, alkyl [(1R,2S,5R (-)-1-
menthoxyacetyl]pyrrolidinium chloride, was dried in a
vacuum line overnight. In the second step, chloride of the
ionic liquid was replaced with tetrafluoroborate,
hexafluorophosphate, bistrifluoromethane sulfonimide, or L-
lactate by reacting with HBF4, KPF6, or bis(trifluoromethane)
sulfonimide lithium salt in water or sodium L-lactate in
acetone, respectively. The product was extracted into
methylene chloride (2 x 10 mL) and the combined organic
layers were dried with anhydrous Na2SO4. The solvent was
evaporated using a rotary evaporator and the final ionic
liquids were dried in a vacuum line prior to characterization.
Table
2,
2d:
Butyl
[(1R,2S,5R)-(-)-
menthoxyacetyl]pyrrolidinium L-lactate (semisolid; yield =
1
84.4%), []20 -39.8; H NMR (400 MHz, CDCl3, ): 4.65
D
(dt, J = 4.0, 10.4 Hz, 1H), 4.62, 4.36 (d, J = 7.6 Hz, 2H), 4.05
(q, J = 5.5 Hz, 1H), 3.75 (t, J = 5.7 Hz, 4H), 3.42 (t, J = 5.9
Hz, 2H), 2.93 (bs, 1H, OH), 2.20 (t, J = 5.6 Hz, 4H), 1.55-
1.52 (m, 2H), 1.29-1.26 (m, 2H), 1.19 (d, J = 6.0 Hz, 3H),
2.07–0.98 (m, 9H), 0.88 (t, J = 6.7 Hz, 3H), 0.76 (d, J = 7.0
Hz, 3H), 0.74 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.8 Hz, 3H);
13C NMR (100 MHz, CDCl3, δ): 182.4, 164.7, 77.6, 71.1,
67.9, 64.4, 64.0, 60.2, 46.6, 40.5, 34.5, 31.6, 25.6, 25.3, 23.6,
21.8, 21.6, 21.2, 20.7, 20.3, 19.7, 16.0, 13.5; IR (/cm-1):
2996, 1758, 1749, 1233, 1016.
Methyl
[(1R,2S,5R)-(-)-menthoxyacetyl]pyrrolidinium
chloride (91%), []20 -54.0; 1H NMR (400 MHz, CDCl3, ):
D
4.91, 4.75 (d, J = 11.1 Hz, 2H), 4.71 (dt, J = 4.5, 11.1 Hz,
1H), 3.98 (t, J = 5.8 Hz, 4H), 3.37 (s, 3H), 2.20 (t, J = 5.8 Hz,
4H), 2.05–0.95 (m, 9H), 0.90 (d, J = 7.5 Hz, 3H), 0.80 (d, J =
6.7 Hz, 3H), 0.76 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz,
CDCl3, δ): 165.0, 77.6, 71.1, 65.2, 65.1, 50.1, 46.4, 40.6, 33.7,
31.5, 26.1, 23.1, 21.8, 21.4, 21.0, 20.8, 16.1; IR (/cm-1):
2980, 1740, 1180, 1090.
18. All products exhibited spectral properties consistent
with the assigned structures. Butyl [(1R,2S,5R)-(-)-
menthoxyacetyl]pyrrolidinium chloride (87%), []20 - 35.2;
D
1H NMR (400 MHz, CDCl3, ): 4.60 (dt, J = 4.2, 10.1 Hz,
1H), 4.54, 4.27 (d, J = 10.6 Hz, 2H), 3.98 (t, J = 5.8 Hz, 2H),
3.70 (t, J = 5.8 Hz, 2H), 3.39 (t, J = 5.8 Hz, 2H), 2.13 (t, J =
Table
2,
2e:
Methyl
[(1R,2S,5R)-(-)-
menthoxyacetyl]pyrrolidinium tetrafluoroborate (solid; m.p. =